Getinge (OTCMKTS:GNGBY) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Getinge (OTCMKTS:GNGBY) from a hold rating to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

Getinge Stock Up 0.2%

Shares of OTCMKTS GNGBY opened at $23.96 on Tuesday. Getinge has a 52-week low of $18.99 and a 52-week high of $24.67. The firm has a market capitalization of $6.53 billion, a price-to-earnings ratio of 22.82 and a beta of 0.96. The stock has a 50 day moving average price of $20.86 and a 200 day moving average price of $21.33. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.86 and a current ratio of 1.32.

Getinge (OTCMKTS:GNGBY) last released its quarterly earnings data on Friday, July 17th. The company reported $0.38 EPS for the quarter. Getinge had a return on equity of 11.67% and a net margin of 7.81%.The company had revenue of $894.87 million for the quarter. Sell-side analysts expect that Getinge will post 1.38 earnings per share for the current year.

About Getinge

Getinge AB is a global medical technology company that develops, manufactures and markets products and systems for hospitals and life sciences institutions. The company’s offerings focus on critical care, surgical workflows and infection control, aiming to improve clinical outcomes and operational efficiency. Getinge’s solutions support a range of applications from intensive care and cardiovascular treatments to sterile reprocessing of surgical instruments.

The company’s product portfolio includes sterilization and disinfection equipment, surgical tables and lights, ventilation systems, heart-lung machines and extracorporeal membrane oxygenation (ECMO) devices.